Sandy mom of six survives 15 years of blood cancer, helps other patients fight
Jenny Ahlstrom, 57, was diagnosed with , a form of blood cancer, in 2010. Following her diagnosis, she was presented with a lot of options for treatment.
'It's really hard to figure out, as a patient, what to do,' Ahlstrom told ABC4. 'I was looking for strategies where I could get treated and not have to be treated for a long time.'
A turning point in Ahlstrom's battle was receiving a known as CAR-T during clinical trials. The treatment, much like dialysis, included the removal of her blood cells, changing them in a lab, then infusing the cells back into her through an IV drip.
'Taking care of Jenny and taking care of her family… has just been remarkable,' Ahlstrom's doctor, Doug Sborov, said.
'Blessed and grateful': Teen survivor of West Valley murder-suicide graduates high school
According to Sborov, an Associate Professor at the University of Utah's Huntsman Cancer Institute, multiple myeloma is generally considered to be 'incurable.' However, with new research and medications, like CAR-T, physicians can drastically lengthen patients' lives and improve their quality of life.
'Here I am, three years later, completely disease free,' Ahlstrom said.
'She's provided patients an incredible opportunity to be educated. She's provided researchers, like myself, an incredible opportunity to engage with patients and really fundamentally change how we're approaching how we take care of these folks,' Sborov told ABC4.
Jenny Ahlstrom raises awareness about available resources for blood cancer patients. (Courtesy Stacey Isaacs)
Now, Ahlstrom leads a nonprofit called that raises awareness and increases access to vital data for researchers.
'If we're going to make advances in healthcare, we need to leapfrog forward in innovation,' Ahlstrom said.
Ahlstrom says there are about 35,000 new diagnoses of myeloma every year and 150,000 living patients with myeloma.
'It's really amazing to bring these new types of therapy to these patients,' Ahlstrom said. 'It's available and it's here.'
Trump to pardon reality TV stars Todd and Julie Chrisley
Sandy mom of six survives 15 years of blood cancer, helps other patients fight
Orem woman allegedly blocks driver, causing 'significant congestion' during road rage incident
RFK Jr. ends COVID shot recommendation for healthy kids, pregnant women
President Trump appears to lose patience with Putin
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline
AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a 'high-risk, high-reward' clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T therapy that overcomes limitations with current options. Currently approved therapies of this kind act by upgrading patient-extracted T cells' ability to fight cancer cells, but this method has financial and scalability hurdles, along with a lymphodepleting chemo requirement, curbing uptake. Capstan's lead asset, CPTX2309, is an in vivo targeted lipid nanoparticle (LNP) anti-CD19 CAR-T therapy that could solve these issues. AbbVie certainly sees the promise in the drug, paying $2.1bn upfront to take control of the CAR-T therapy alongside other preclinical programmes and the RNA payload-delivering technology used to create them. CPTX2309, being developed for the treatment of B-cell-mediated autoimmune diseases, is already being evaluated in a Phase I study (NCT06917742) with healthy volunteers. A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an 'immune reset' by repopulation of healthy B cells. Investors shared positive sentiment in the acquisition, with shares in NYSE-listed AbbVie closing 1.7% higher at $185.62 on 30 June, the day the announcement was made. The big pharma has a market cap of $327.9bn. This is not the first in vivo CAR-T relationship that AbbVie has fostered, with a collaboration with Umoja Biopharma in January 2024. This partnership allows AbbVie to develop in-situ generated CAR-T cell therapy candidates in oncology using Umoja's VivoVecplatform. William Blair analyst Matt Phipps said in a research note: 'While CPTX2309 is still in early clinical development, we believe the acquisition shows a strategic effort by AbbVie to further strengthen its immunology franchise through novel, disease-modifying mechanisms. 'Given the stage of development, this asset clearly comes with clinical risk, but given the potential of in vivo CAR-T, which does not require lymphodepletion and has potential for greater manufacturing scalability, it offers significant long-term upside if successful.' Phipps, who described AbbVie's new asset as 'high-risk, high-reward,' said the purchase consolidates AbbVie's strong trading. The big pharma company has already shrugged off the loss of market exclusivity for its blockbuster Humira (adalimumab) by rolling out Skyrizi (risankizumab) and Rinvoq (upadacitinib). According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an 'attractive opportunity' for long-term investors. Capstan's CEO Laura Shawver said: "In vivo CAR-T represents a potential new treatment modality in medicine – embodying the transformative power of cell therapy with the accessibility and scalability of an off-the-shelf biologic. This technology has the potential to become a first-in-class platform to treat a wide range of autoimmune diseases.' Interius BioTherapeutics and Umoja Biopharma are two biotechs in the in vivo CAR-T arena that have assets in clinical trials targeting oncological indications. These assets also use lentiviral vectors to generate the cells in vivo, whereas Capstan is using mRNA. CPTX2309 is built on Capstan's targeted LNP platform to enable in vivo delivery of RNA payloads to target cells. CPTX2309 is made up of an anti-CD19 CAR mRNA payload inside an LNP. AbbVie's purchase comes just a few days after the US Food and Drug Administration (FDA) removed an access barrier for currently approved CAR-T therapies, regarded as a boost to the sector's outlook. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. "AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Journals
12 hours ago
- Business Journals
Atrium Health Levine Children's Brenner Children's Hospital patient throws first pitch at Dash game
15-year-old Jamon King was diagnosed with T-Cell Leukemia in January of 2023. It started as a stomachache that wouldn't go away. His mother took him to the doctor seeking answers and learned the devastating news. Jamon immediately began his treatment at Atrium Health Levine Children's Brenner Children's Hospital. During his time at Brenner Children's Hospital, Jamon discovered his love for art. Prior to his diagnosis, Jamon enjoyed basketball and football, but after staying at the hospital he found a new passion. In February, Jamon worked with the Winston-Salem Dash team to create an ice cream inspired jersey to be worn by players during the Stand Up to Cancer game. On Saturday, June 14, Jamon threw out the first pitch at the Winston-Salem Dash Stand Up to Cancer game. Later in the game, he was recognized for his bravery battling T-Cell Leukemia. Players also wore a special jersey designed by Jamon. He was excited to see his design come to life on the field. 'No matter what you're going through, keep pushing because God is going to make a way,' Jamon said. 'Trust the group of people supporting you, no matter how big or small your group is. Find a group of people that believe in you as much as you believe in yourself.' Atrium Health Wake Forest Baptist is a pre-eminent academic learning health system based in Winston-Salem, North Carolina, and part of Advocate Health. Atrium Health Wake Forest Baptist's two main components are an integrated clinical system with locations throughout the region and
Associated Press
a day ago
- Associated Press
Therapist turns personal immigration story into lifeline for others amid rising ICE concerns
LOS ANGELES, CA, UNITED STATES, June 30, 2025 / / -- As national outrage grows over recent deaths and civil rights violations involving U.S. Immigration and Customs Enforcement (ICE), California-based therapist Dora Valencia steps forward to help people navigate the legal system through trauma-informed immigration evaluation services. Valencia, a licensed clinical social worker, draws on her own immigration story to support individuals facing cases related to the Violence Against Women Act (VAWA), U-visa, T-visa and Extreme Hardship waivers. She provides culturally responsive psychological evaluations to help clients tell their stories in support of immigration relief. Born in Mexico and brought to the U.S. as a baby, Valencia spent her early childhood undocumented just miles from a border checkpoint. She doesn't recall being afraid of the checkpoint itself due to her age, but she does remember the constant need to stay cautious and aware. She learned what to say and how to carry herself if approached by border patrol. 'People don't leave home without a reason, whether it be fear of persecution, poverty, violence, or something just as challenging,' said Valencia. 'Those who immigrate to the United States are truly looking for a better life and America has always been seen as the land of promise and dreams. They see America as an opportunity to work hard and provide for their family.' Now, as headlines expose alarming ICE facility conditions and the ongoing trauma endured by asylum seekers, Valencia's work is timelier than ever. Expert immigration evaluations help nearly 90 percent of cases secure relief. A study analyzing 2,584 immigration cases that included forensic medical evaluations (covering both physical and psychological assessments) found that 81.6% resulted in a positive outcome, which is significantly higher than the national average grant rate of 42.4% during the same period. Valencia offers immigration evaluation services amid growing national concerns around immigrant safety and due process. She serves clients across California through secure Telehealth sessions in both English and Spanish. To schedule an appointment with Dora Valencia, LCSW, contact Lisa Eaton Therapy and Coaching's Intake Coordinator at 949-236-1990 or [email protected]. Lisa Eaton Therapy and Coaching is a California-based TeleHealth practice committed to doing therapy differently. Founded by licensed therapist and coach Lisa Eaton, the practice offers high-quality, results-driven mental health and coaching services designed to help clients feel truly supported and guided through life's challenges. Since launching in 2021 as a group practice, Lisa Eaton Therapy has expanded its reach while maintaining a high-touch, compassionate approach rooted in clinical expertise and human connection. Serving clients across California, including Irvine, Los Angeles, San Diego and beyond, the practice prioritizes client experience, cultural responsiveness and lasting change. Learn more at Lisa Eaton Owner, Lisa Eaton Therapy and Coaching +1 (949) 236-1990 email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
